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OBJECTIVES We sought to compare emergency coronary angiography with or without rescue percutaneous
coronary intervention (PCI) with conservative treatment in patients with failed fibrinolysis
complicating ST-segment elevation myocardial infarction (STEMI).
BACKGROUND Most patients with STEMI receive fibrinolytic therapy and aspirin. The management of
failed fibrinolysis is unclear.
METHODS A total of 307 patients with STEMI and failed fibrinolysis were randomized to emergency
coronary angiography with or without rescue PCI or conservative treatment.
RESULTS Thirty-day all-cause mortality was similar in the rescue and conservative groups (9.8% vs.
11%, p  0.7, risk difference [RD] 1.2%, 95% confidence interval [CI] 5.8 to 8.3). The
composite secondary end point of death/re-infarction/stroke/subsequent revascularization/
heart failure occurred less frequently in the rescue group (37.3% vs. 50%, p  0.02, RD
12.7%, 95% CI 1.6 to 23.5), driven by less subsequent revascularization (6.5% vs. 20.1%, p 
0.01, RD 13.6%, 95% CI 6.2 to 21.4). Re-infarction and clinical heart failure were less
common in the rescue group (7.2% vs. 10.4%, p  0.3, RD 3.2%, 95% CI 3.3 to 9.9; and
24.2% vs. 29.2%, p  0.3, RD 5.7%, 95% CI 4.3 to 15.6, respectively). Strokes and
transfusions were more common in the rescue group (4.6% vs. 0.6%, p 0.03, RD 3.9%, 95%
CI 0.5 to 8.6; and 11.1% vs. 1.3%, p  0.001, RD 9.8%, 95% CI 4.9 to 19.9, respectively).
Left ventricular function at 30 days was the same in the two groups.
CONCLUSIONS Rescue angioplasty did not improve survival by 30 days, but improved event-free survival,
almost completely due to a reduction in subsequent revascularization. Rescue angioplasty was
associated with more strokes and more transfusions and did not result in preservation of left
ventricular systolic function at 30 days. (J Am Coll Cardiol 2004;44:287–96) © 2004 by the
American College of Cardiology Foundationhe management of patients with acute ST-segment eleva- without recourse to invasive techniques. As a result, many
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herapy is unsuccessful is not clear. This is partly due to the
ifficulty of making the diagnosis of failed thrombolysis
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upport.
Manuscript received October 20, 2003; revised manuscript received December 5,003, accepted December 10, 2003.nits have no structured policy for the management of failed
hrombolysis (1,2). Many clinicians follow a conservative
pproach, allowing more time for fibrinolytic therapy to
ork. Others use repeat fibrinolytic therapy (3). Although
escue angioplasty is used in some centers, there are few
andomized trials of this approach. A small trial by Belenkie
t al. (4) had insufficient power to determine a clear
dvantage. A larger study by Ellis et al. (5) compared rescue
ngioplasty with continued conventional medical therapy in
atients with a first anterior myocardial infarction (MI) and
emonstrated a trend toward a reduction in the incidence of
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The MERLIN Trial July 21, 2004:287–96he non-prespecified end point of 30-day death or severe
eart failure in the rescue arm (6% vs. 17%, p  0.05).
hese studies investigated rescue angioplasty without the
otential benefits of coronary stenting and pharmacologic
djuncts such as glycoprotein IIb/IIIa inhibitors. Their
esults have not provided clear guidance on whether cardiac
nits should actively seek the diagnosis of failed fibrinolysis
ith the aim of providing rescue angioplasty.
Transfer of selected patients receiving fibrinolytic ther-
py, with a view to rescue angioplasty, has been shown to be
elatively safe and associated with a favorable outcome (6,7).
he strategy of rescue angioplasty for failed fibrinolysis,
ncluding the transfer of patients from non-interventional
enters, has not been re-assessed in prospective, randomized
rials in the modern angioplasty era. The Middlesbrough
arly Revascularization to Limit INfarction (MERLIN)
rial was designed to compare a rescue angioplasty strategy
ith continued medical treatment for patients with acute
TEMI and failed fibrinolysis.
ETHODS
articipating hospitals. The trial center was The James
ook University Hospital, Middlesbrough, a Regional Car-
iothoracic Unit, where all emergency coronary angiogra-
hy and subsequent revascularization procedures were per-
ormed. Patients were enrolled from the Coronary Care
nit at The James Cook University Hospital and the
ccident and Emergency Unit of the affiliated Middles-
rough General Hospital. Patients were also enrolled from
he Coronary Care Units at the University Hospital of
orth Tees, Stockton-on-Tees, and Darlington Memorial
ospital, Darlington.
nclusion criteria. Patients with STEMI and evidence of
ailure to respond to the administration of fibrinolytic
herapy constituted the trial population. Presentation to the
ospital within 10 h of the onset of major symptoms was
equired. Myocardial infarction was defined by the presence
f ischemic chest pain lasting more than 30 min, unrelieved
y sublingual nitrate and associated with typical ST-
egment elevation on the 12-lead electrocardiogram (ECG;
t least 2 mm of ST-segment elevation in 2 or more
ontiguous chest leads and at least 1 mm in 2 or more
ontiguous limb leads). Failure to respond to fibrinolytic
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
LV  left ventricular
MERLIN  Middlesbrough Early Revascularization to
Limit INfarction trial
PCI  percutaneous coronary intervention
RD  risk difference
RWMI  regional wall motion index
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarctionherapy was defined by a second 12-lead ECG obtained 60 tin after the onset of fibrinolytic therapy, showing failure of
he ST-segment elevation in the worst lead (the lead with
aximal ST-segment elevation) to have resolved by 50%, as
ompared with the pretreatment ECG (ST-segment mea-
ured 80 ms after the J point), as well as the absence of an
ccelerated idioventricular rhythm at the time of the 60-min
CG (8).
xclusion criteria. These included cardiogenic shock (de-
ned by systolic blood pressure 90 mm Hg, oliguria, and
oor peripheral perfusion with or without clinical or radio-
ogic evidence of pulmonary edema); confounding features
n the prefibrinolytic ECG, preventing ST-segment reduc-
ion analysis; re-infarction in the same ECG territory
ithin two months of an original infarction; absent femoral
ulses; pregnancy; and the presence of significant co-
xisting pathology likely to affect the prognosis during the
ollow-up period.
dditional treatment. Patients fulfilling the inclusion cri-
eria were treated initially with 300 mg aspirin and there-
fter at least 75 mg/day aspirin. The administration of other
harmacologic agents, such as beta-blockers, calcium chan-
el antagonists, nitrates, antithrombotic agents, and other
ntiplatelet agents (e.g., thienopyridines and glycoprotein
Ib/IIIa inhibitors) in either arm was at the discretion of the
ttending physician or cardiologist.
andomization. Randomization was by a telephone call to
he Coronary Care Unit at The James Cook University
ospital. The patient was assigned to: 1) rescue angioplasty;
r 2) conservative therapy by means of a sealed envelope
ystem. The randomization sequence was created from
tandard random number charts and was a block random-
zation process (block size 4), ensuring equal numbers of
atients in each arm of the trial after every four randomized
atients and approximately equal numbers overall.
ESCUE ANGIOPLASTY. Patients randomized to the rescue
ngioplasty arm were transferred urgently to the cardiac
atheterization laboratory at The James Cook University
ospital as soon as the 60-min ECG confirmed persistent
T-segment elevation and consent had been obtained.
oronary angiography was performed from any arterial
ccess point, and percutaneous coronary intervention (PCI)
as attempted if considered appropriate. Unfractionated
eparin was administered to all patients undergoing PCI
ho had a target activated clotting time of 300 s at the time
f intervention. The use of intracoronary stents, an intra-
ortic balloon pump, other mechanical devices, and adjunc-
ive pharmacologic therapy was at the discretion of the
ttending cardiologist. After angioplasty, all patients con-
inued to take regular aspirin, at least 75 mg/day, in the
bsence of a history of allergy. If one or more coronary
tents were deployed, ticlopidine 250 mg twice daily follow-
ng an initial immediate dose of 500 mg, or clopidogrel 75
g/day following an initial dose of 300 mg, was adminis-
ered. Electrocardiography was performed every 3 h after
he initiation of fibrinolytic therapy for 24 h.
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July 21, 2004:287–96 The MERLIN TrialONSERVATIVE ARM. Patients in the conservative arm re-
eived standard medical treatment after the administration
f fibrinolytic therapy. The use of repeat fibrinolytic therapy
as discouraged but allowed during the trial if this was
tandard local policy. The use of heparin and other treat-
ents was at the discretion of the attending physician. Early
rossover to the rescue angioplasty arm was not allowed,
xcept for when cardiogenic shock developed. Electrocardi-
graphy was performed every 3 h after the initiation of
brinolytic therapy for 24 h. Angiography and revascular-
zation were permitted for re-infarction (defined subse-
uently) or for recurrent ischemia or a positive exercise test
uring the hospital admission.
thical considerations. The study received approval from
he Local Research Ethics Committee for each of the
articipating hospitals. Informed, written consent from each
atient was required for trial entry, taken in the presence of
relative if possible. A Data and Safety Monitoring Com-
ittee was established to review the results of the trial after
nrolment of the first 100 and 200 patients and recom-
ended trial continuation at each stage. Adverse events
ere monitored continuously. Initial follow-up was planned
or a period of six months, but subsequently extended to
hree years with agreement of the Ethics Committees.
xercise testing and echocardiograms. After the index
vent, the assessment of inducible ischemia and left ventric-
lar (LV) systolic function was arranged in accordance with
ocal guidelines. Formal assessment of LV function was
erformed at 30 days and six months by two experienced
chocardiographers (Drs. Price and Graham), and all im-
ges were analyzed by a single observer (Dr. Graham), who
as blinded to the treatment strategy. The 16-segment
odel for assessment of LV function, as recommended by
he American Society of Echocardiography, was used, with
he function of each segment scored as follows: 1 normal;
 hypokinetic; 3  akinetic; 4  dyskinetic; and 5 
neurysmal (9). The regional wall motion index (RWMI)
as calculated.
nd points and definitions. The primary end point was
ll-cause mortality at 30 days. The secondary end points
ere: 1) a composite of death, re-infarction, stroke, heart
ailure, and clinically driven subsequent revascularization
ithin 30 days; and 2) LV function at 30 days, as assessed
y RWMI. The primary and secondary end points will be
e-evaluated at six months and annually to three years.
Re-infarction was defined by a repeat episode of ischemic
hest pain after recovery from the initial event, associated
ith typical ST-segment re-elevation on the ECG and
asting for 30 min despite opiate and nitrate therapy.
troke was defined by any new neurologic deficit lasting
24 h; computed axial tomography was performed when
ossible. Heart failure was defined by the requirement for
iuretic treatment in the presence of typical chest X-ray
haracteristics, or auscultatory crackles extending at least
ne-third of the way up the lung fields without a previous
istory of chronic pulmonary disease, or a third heart sound tith persistent tachycardia. Subsequent revascularization
as defined by any catheter-based or surgical intervention in
he conservative group and any additional revascularization
rocedure in the rescue group that was not planned after the
nitial coronary angiogram.
Procedural success in the rescue angioplasty arm was
efined by the presence of Thrombolysis In Myocardial
nfarction (TIMI) flow grade 2 or 3 in the infarct-related
essel with 50% residual stenosis and no requirement for
mergency coronary artery bypass graft surgery (CABG) as
he result of a complication of PCI and the patient being
ransferred back to the coronary care unit.
tatistical methods. All end points were analyzed on an
ntention-to-treat basis. Statistical comparisons between the
roups were made using chi-square analysis for the categor-
cal variables, with calculation of the risk difference (RD)
nd 95% confidence interval (CI). The Fisher exact test was
sed where expected values were5. The t test was used for
ontinuous end points, and the difference in mean values
ith 95% CI was presented. Logistic regression was used to
est for an association between specified variables and
utcome. Survival and survival without occurrence of one
or more) of the individual end points were plotted on
aplan-Meier curves.
The sample size was estimated on the basis of the
ollowing assumptions: from a review of the literature, the
rimary end point would occur in 18% of those in the
onservative arm (10,11) and in 6% of those in the rescue
ngioplasty arm (4,5,12–16), based on the available pub-
ished data. Approximately 150 patients would be required
n each arm to detect a mortality difference between 18% in
he conservative group and 6% in the salvage group, with
0% power and a p value of 0.05.
ESULTS
atients were enrolled into the study between February
999 and June 2002. Enrollment in each center was as
ollows: The James Cook University Hospital, n 176; The
niversity Hospital of North Tees, n  107 (from June
999); and The Darlington Memorial Hospital, n  24
from July 2000). A total of 154 patients were randomized
o the conservative arm and 153 to the rescue angioplasty
rm. Streptokinase was administered to 149 patients in the
onservative arm and 147 patients in the rescue angioplasty
rm, with the remaining 11 patients receiving recombinant
issue-type plasminogen activator (rt-PA). There were no
ignificant differences in the baseline characteristics of
atients between the two groups, with the exception of the
ean total cholesterol, which was slightly higher in the
escue angioplasty arm (Table 1).
In the rescue angioplasty arm, the mean time from the
nset of chest pain to coronary angiography was 327  121
in. The mean time from the 60-min ECG to coronary
ngiography was 85  36 min (this includes the time from
he recording of the 60-min ECG to obtaining informed
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The MERLIN Trial July 21, 2004:287–96onsent). Four patients did not have a coronary angiogram:
ne patient with hematemesis on arrival in the catheteriza-
ion laboratory and improvement of the ECG compared
ith the postfibrinolytic ECG; one patient in whom the
oronary ostia could not be engaged from the right femoral
rtery due to extreme iliac artery tortuosity; one patient with
preexisting diagnosis of severe triple-vessel coronary dis-
ase unsuitable for PCI and who had ECG evidence of
eperfusion on arrival; and one patient with ECG evidence
f reperfusion who did not have coronary angiography due
o misinterpretation of the trial protocol. All four were
ncluded on an intention-to-treat basis. The angiographic
ndings and subsequent management in the rescue angio-
lasty arm patients are shown in Figure 1. In 77 (94%) of
able 1. Demographic Details
Conservative
Arm
(n  154)
Rescue Angioplasty
Arm
(n  153)
ale (%) 114 (74) 108 (71)
ge (yrs) 62.7  10.9 63.0  11.2
istory of hypertension (%) 47 (30.5) 62 (40.5)
istory of diabetes (%) 23 (14.9) 18 (11.8)
nsulin therapy (%) 7 (4.5) 4 (2.6)
nown hyperlipidemia (%) 24 (15.6) 29 (19.0)
otal cholesterol on
admission (mmol/l)
5.54  1.17 5.82  1.32*
lood glucose on admission
(mmol/l)
8.9  3.0 9.0  3.3
urrent smoker (%) 57 (37.0) 64 (41.8)
x-smoker (%) 51 (33.1) 45 (29.4)
revious MI (%) 20 (13.0) 17 (11.1)
nterior MI (%) 62 (40.3) 74 (48.4)
ain to lysis time (min) 170  96 180  120
ysis to laboratory time (min) — 146  37
ain to laboratory time (min) — 327  121
p  0.05. Data are presented as the mean value  SD or number (%) of patients.
MI  myocardial infarction.
igure 1. Rescue angioplasty patients, showing catheterization laboratory
Thrombolysis In Myocardial Infarction [TIMI] flow grade 2 or 3), no eme
evasc  subsequent revascularization; CCF  congestive cardiac failure; IRVhe 82 patients undergoing intervention for TIMI flow
rade 3, PCI was successful. A total of 130 patients in the
escue arm (85%) left the catheterization laboratory with
IMI flow grade 3 in the infarct-related vessel. The
anagement, medications, and complications for all pa-
ients are shown in Table 2.
The 30-day end points are shown in Table 3. The
rimary end point of all-cause mortality occurred in 15
atients in the rescue angioplasty arm and 17 patients in the
onservative arm (9.8% vs. 11%, p 0.7, RD 1.2%, 95% CI
5.8 to 8.3; chi-square test). Two patients in the rescue
ngioplasty arm died of noncoronary causes before 30 days
1 killed on day 24 in a road traffic accident and 1 with a
ormal coronary arteriogram who died on day 2 with a
ostmortem diagnosis of acute myocarditis). Thirty-day
ortality attributable to coronary artery disease was 8.5% in
ngs and outcomes. “Success” was defined by patent infarct-related vessel
y coronary artery bypass graft, and survival during the procedure. Unsched
able 2. In-Hospital Treatment
Conservative
Arm
(n  154)
Rescue
Angioplasty
Arm
(n  153)
mmediate coronary angiography (%) 0 149 (97.4)
mmediate coronary angioplasty (%) 0 100 (65.4)
tent(s) deployment (%) 0 77 (50.3)
lycoprotein IIb/IIIa inhibitor (%) 0 5 (3.3)
ABP (%) 0 19 (12.4)
ransfusion (%) 2 (1.3) 17 (11.1)
ischarge medication*
Aspirin (%) 135 (97.1) 136 (97.8)
Thienopyridine (%) 21 (15.1) 84 (60.4)
Warfarin (%) 4 (2.9) 6 (4.3)
Beta-blocker (%) 114 (82.0) 110 (79.1)
Lipid-lowering medication (%) 101 (72.7) 98 (70.5)
ACE inhibitor (%) 97 (69.8) 109 (78.4)
In each arm, 139 patients were discharged from the hospital.
ACE  angiotensin-converting enzyme; IABP  intra-aortic balloon pump.findi
rgenc infarct-related vessel; PCI  percutaneous coronary intervention.
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July 21, 2004:287–96 The MERLIN Trialhe rescue arm and 11.0% in the conservative arm (p  0.4,
D 2.5%, 95% CI 4.3 to 9.5; chi-square test). Causes of
eath in the 32 patients who died were: progressive cardiac
hock (n  21), cardiac arrest with failed resuscitation (n 
), myocarditis (n  1), re-infarction (n  1), probable
ntracerebral hemorrhage (n  1), presumed cardiac dys-
hythmia (n  3), and a road traffic accident (n  1).
In the rescue angioplasty arm, seven patients underwent
mergency subsequent revascularization for re-infarction:
ve by PCI and two by CABG. Three patients with
e-infarction were managed conservatively: one patient with
e-occlusion of a saphenous vein graft; one patient who had
ustained a stroke seven days after the initial PCI and who
ustained a re-infarction on day 30; and one patient with
evere aortic arch dilation, who subsequently required un-
lanned urgent CABG after re-admission with unstable
ngina. One other patient had a re-infarction and died
efore further intervention could be performed. Two pa-
ients with TIMI flow grade 3 in the infarct-related vessel at
nitial angiography and who did not undergo rescue PCI
nderwent unplanned PCI for postinfarction angina (n 1)
r a significantly positive exercise treadmill test (n  1).
hus, re-infarction occurred in 11 patients and subsequent
evascularization in 10 patients in the rescue arm.
In the conservative arm, unscheduled emergency PCI was
erformed in 11 patients for re-infarction, in two patients
ho developed cardiogenic shock as a complication of the
riginal STEMI, and in two patients with postinfarction
nstable angina (both of whom had also sustained a re-
nfarction treated with second doses of fibrinolytic therapy).
mergency CABG and patch repair were performed in one
atient who developed a postinfarction ventricular septal
efect, and urgent CABG was performed in one patient
ith postinfarction angina and severe triple-vessel coronary
isease. Another 14 patients in the conservative arm re-
uired unscheduled PCI for postinfarction angina with
CG changes (n  8) or a positive inpatient exercise
readmill test (n  6). Another three patients in the
onservative arm sustained a re-infarction but did not
ndergo revascularization: one patient treated with further
brinolytic therapy; one who declined coronary angiography
nd was managed conservatively; and one who developed a
entricular septal defect after a re-infarction and who died
able 3. Thirty-Day End Points
Conservative Arm
(n  154)
eath (%) 17 (11.0)
ubsequent revascularization (%) 31 (20.1)
troke (%) 1 (0.6)
e-infarction (%) 16 (10.4)
eart failure (%) 46 (29.9)
omposite secondary end point (%) 77 (50)
Conservative–rescue angioplasty difference.
CI  confidence interval; RD  risk difference.ithout attempted revascularization. Thus, re-infarctionccurred in 16 patients and subsequent revascularization in
1 patients in the conservative arm.
There was no significant difference in the incidence of
e-infarction in the rescue angioplasty arm compared with
he conservative arm (7.2% vs. 10.4%, p  0.3, RD 3.2%,
5% CI3.3 to 9.9; chi-square test), but there was a highly
ignificant reduction in the incidence of subsequent revas-
ularization (6.5% vs. 20.1%, p  0.01, RD 13.6%, 95% CI
.2 to 21.4; chi-square test).
The incidence of clinical heart failure requiring hospital
reatment in the first 30 days was 24.2% in the rescue arm
nd 29.2% in the conservative arm (p  0.3, RD 5.7%, 95%
I 4.3 to 15.6; chi-square test).
Stroke occurred in seven patients in the rescue angio-
lasty arm and one patient in the conservative arm (4.6% vs.
.6%, p  0.03, RD 3.9%, 95% CI 0.5 to 8.6; Fisher exact
est). In the rescue arm, one stroke was fatal (a computed
omographic scan could not be performed, but the clinical
resentation suggested intracranial hemorrhage). There
ere six thromboembolic strokes, as confirmed by computed
omography (n  5) or magnetic resonance imaging (n 
), two of which resulted in long term disability. One of the
hromboembolic strokes occurred in a patient who did not
ndergo coronary angiography or attempted rescue PCI
ecause of hematemesis, and one occurred in a patient with
ocumented LV thrombus. Three strokes in the rescue arm
ccurred within the first 24 h and were more readily
ttributable to the procedure. For patients with anterior
TEMI in the rescue arm, the incidence of stroke was 6.8%.
he single stroke in the conservative arm was thromboem-
olic in nature, as judged by clinical presentation, but was
ot disabling. Eighteen patients in the conservative arm
11.7%) received additional fibrinolytic therapy as part of
he management of initial failed fibrinolysis, but there were
o episodes of intracranial hemorrhage in this small group.
The composite secondary end point occurred in 57
atients in the rescue angioplasty arm and 77 patients in the
onservative arm (37.3% vs. 50.0%, p  0.02, RD 12.7%,
5% CI 1.6 to 23.5; chi-square test).
Although not a prespecified analysis, the end points for
atients with an anterior MI are shown in Table 4.
Survival and event-free survival are shown in Figures 2
nd 3. At 30 days, the RWMI was 1.52 in the rescue
scue Angioplasty Arm
(n  153) p Value RD* (%) (95% CI)
15 (9.8) 0.7 1.2 (5.8 to 8.3)
10 (6.5) 0.01 13.6 (6.2 to 21.4)
7 (4.6) 0.03 3.9 (8.6 to 0.5)
11 (7.2) 0.3 3.2 (3.3 to 9.9)
37 (24.2) 0.3 5.7 (4.3 to 15.6)
57 (37.3) 0.02 12.7 (1.6 to 23.5)Re
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The MERLIN Trial July 21, 2004:287–96roup and 1.58 in the conservative group, a difference of
0.06 (95% CI 0.15 to 0.03) (Table 5).
The only univariate predictor of all-cause mortality by 30
ays was anterior MI (odds ratio [OR] 4.37, 95% CI 1.89 to
0.10). Anterior MI was also a univariate predictor of the
omposite secondary end point (OR 2.33, 95% CI 1.47 to
.71). Predictors of the composite secondary end point by
ultivariate logistic regression analysis are shown in Table
. Anterior MI, female gender, and conservative treatment
ere predictors of reaching the composite secondary end
oint. Multivariate predictors of major adverse cardiac
vents (death, re-infarction, or subsequent revasculariza-
ion) were anterior MI and conservative treatment, although
his was not a prespecified analysis. Further analysis of the
escue group demonstrated that implantation of one or more
oronary stents was not a predictor of freedom from the
omposite secondary end point or from major adverse
ardiac events.
Analysis by actual treatment received, as opposed to the
ntention-to-treat principle, showed results similar to those
n Table 3, with the exception of a statistically significant
eduction in the incidence of clinical heart failure in the
escue group (19.8% vs. 30.6%, p  0.046, RD 10.8%, 95%
I 0.2 to 20.3).
able 4. Thirty-Day End Points for Anterior Myocardial Infarcti
Conservative Arm
(n  62)
eath (%) 12 (19.3)
ubsequent revascularization (%) 14 (22.6)
troke (%) 1 (1.6)
e-infarction (%) 8 (12.9)
eart failure (%) 24 (38.7)
omposite secondary end point (%) 39 (62.9)
Conservative–rescue angioplasty difference.
Abbreviations as in Table 3.Figure 2. Thirty-day Kaplan-Meier survival curve. Dotted lineIn both groups, the incidence of the primary and second-
ry composite end points was higher in patients with
ersistent ST-segment elevation 6 h after initiation of
brinolytic therapy than in those with ST-segment resolu-
ion by 50% in the worst lead. There was a borderline
tatistically significant difference between the proportion of
atients in the rescue arm and those in the conservative arm
eveloping ST-segment resolution by 6 h (61.4% vs. 50.5%,
 0.05). In the rescue arm, there was a highly statistically
ignificant difference in the 30-day mortality for patients
ith persistent ST-segment elevation at 6 h, as compared
ith those with ST-segment resolution (20.3% vs. 3.2%, p
0.001), and a similar reduction in the incidence of the
omposite secondary end point (47.5% vs. to 30.9%, p 
.04). These differences were less marked in the conserva-
ive group (Fig. 4).
Transfusion was required in 17 patients in the rescue
ngioplasty arm, compared with two in the conservative arm
11.1% vs. 1.3%, p 0.001, RD 9.8%, 95% CI 4.9 to 19.9).
ransfusion was reserved for those with a fall in hemoglobin
f 2 g/dl, and only if this took the total hemoglobin to
10 g/dl. The majority of the patients in the trial receiving
ransfusion did so for a hemoglobin fall much greater than
g/dl. In the rescue arm, transfusion was required for the
scue Angioplasty Arm
(n  74) p Value RD* (%) (95% CI)
12 (16.2) 0.6 3.1 (9.8 to 16.7)
4 (5.4) 0.003 17.2 (6.0 to 29.8)
5 (6.8) 0.2 5.1 (13.5 to 2.6)
4 (5.4) 0.1 7.5 (2.3 to 18.8)
22 (29.7) 0.3 9.0 (7.0 to 24.8)
36 (48.6) 0.09 14.3 (2.6 to 30.2)on
Re conservative arm; solid line  rescue angioplasty arm.
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July 21, 2004:287–96 The MERLIN Trialollowing: 12 patients for significant groin hematoma (3 of
hom also had upper gastrointestinal bleeding); three pa-
ients for significant gastrointestinal hemorrhage (1 after
ABG); one patient who required blood after urgent
ABG; and one patient with a fall in hemoglobin from 15
o 8 g/dl, with no clear bleeding source. The mean hemo-
lobin value at which transfusion was initiated in the rescue
rm was 8.6 g/dl (95% CI 8.0 to 9.1). None of the 12
atients with groin complications requiring transfusion had
equired intra-aortic balloon pump support. Gastrointesti-
al bleeding, ranging from a small hematemesis requiring
o specific treatment to a duodenal ulcer requiring injection
nd transfusion, occurred in 11 patients in the rescue
ngioplasty arm, six of whom required transfusion, and nine
atients in the conservative arm, two of whom required
ransfusion (7.2% vs. 5.8%, p  0.6, RD 1.3%, 95% CI
4.5 to 7.3).
There was no difference in the length of hospital stay
etween the two arms. In the rescue arm, the median stay
as seven days (range 2 to 46), and in the conservative arm,
he median stay was seven days (range 2 to 23; p  0.95).
ISCUSSION
atients failing to respond to fibrinolytic therapy can be
dentified by persistent ST-segment elevation on the 12-
ead ECG. Persistent ST-segment elevation as soon as 60
in after initiation of fibrinolytic therapy has been shown to
Figure 3. Thirty-day Kaplan-Meier event-free survival curve. D
able 5. Regional Wall Motion Score at 30 Days
Rescue Angioplasty Arm
(n  123)
Cons
(n
ean RWMI 1.52
Rescue angioplasty–conservative difference. Regional wall motion score analysis at 3
rm) because either the patient declined to attend for the study or the endocardial dCI  confidence interval; NS  not significant; RWMI  regional wall motion indexe just as good at identifying high-risk patients as a later
CG (10,11). Repeat fibrinolysis and rescue angioplasty are
robably the most commonly used strategies for failed
eperfusion. In the limited number of patients in whom
econd fibrinolysis has been studied, a benefit has been
onfined to those who had failed to reach a systemic lytic
tate (3).
Most data on rescue angioplasty are from nonrandom-
zed, observational studies. The range of 30-day or hospital
ortality is large, from 2% to 12% (4,5,12–19). In the only
revious reasonably sized, randomized study of rescue an-
ioplasty versus conservative therapy for failed fibrinolysis,
llis et al. (5) demonstrated a borderline statistically signif-
cant reduction in the incidence of death or severe heart
ailure among patients undergoing rescue angioplasty for
ngiographically demonstrated occlusion of the left anterior
escending coronary artery after fibrinolytic therapy for a
rst anterior MI, as compared with those managed conser-
atively (6.4% vs. 16.6%, p  0.05), although this was not
prespecified end point. A low 30-day mortality rate of
.1% in the rescue arm was achieved, even without the
idespread used of stents, glycoprotein IIb/IIIa inhibitors,
nd intra-aortic balloon pumps, the latter being beneficial in
ome patients during rescue angioplasty (20,21).
It is probable that Ellis enrolled lower risk patients than
id MERLIN, on the basis of younger age (mean SD: 59
11 years), shorter chest pain to presentation times (6 h
line  conservative arm; solid line  rescue angioplasty arm.
ve Arm
25)
Difference in Mean Values*
(95% CI) p Value
0.06 (0.15 to 0.03) NS
was not performed in 27 patients (12 in the conservative arm and 15 in the rescue
on was inadequate.ervati
 1
1.58
0 days
efiniti.
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The MERLIN Trial July 21, 2004:287–96equired for trial entry with discretion to extend to 8 h),
horter presentation to angioplasty times (mean 4.5 
.9 h), exclusion of patients with previous MI or left main
tem disease, and overall lower early rates of death (7.3% vs.
7.6%) and heart failure (4% vs. 34%), compared with the
ERLIN trial’s anterior MI subgroup. In addition, the
ecruitment rate of less than three patients per center per
ear suggests a highly selective approach to patient enrol-
ent. Nonetheless, demonstration of a benefit from a rescue
ngioplasty strategy in a low-risk group might be expected
o translate into more benefit in a higher risk group. It is
ossible that higher risk patients might have been enrolled
nto MERLIN by only considering those patients with
ersistent chest pain. However, we do not believe the
resence or absence of chest pain is particularly helpful in
aking the diagnosis of failed fibrinolysis, and the MER-
IN results support this. At the time of coronary angiog-
aphy, TIMI flow in the infarct-related vessel was grade 3
able 6. Predictors of the Composite Secondary End Point by
ultivariate Logistic Regression Analysis
Predictor OR 95% CI
roup
Conservative 1
Angioplasty 0.51 0.32 to 0.83
ender
Male 1
Female 1.99 1.16 to 3.39
ge (yrs)
75 1
75 1.35 0.65 to 2.81
iabetic
No 1
Yes 1.21 0.66 to 2.20
nterior MI
No 1
Yes 2.80 1.71 to 4.57
I  confidence interval; MI  myocardial infarction; OR  odds ratio.
igure 4. Thirty-day mortality according to ST-segment reduction 6 h a
ion.n 53% of those without chest pain and grade 3 in 38% of
hose still in pain.
We have demonstrated that rescue angioplasty has a high
uccess rate in terms of restoring normal anterograde flow in
n occluded or partially occluded vessel. Successful catheter
aboratory outcomes are also achieved in patients with TIMI
ow grade 3 at initial angiography, but who have a critical
oronary artery stenosis. Patients offered urgent rescue
ngioplasty have a significant reduction in the 30-day
ncidence of the combined end point of death, re-infarction,
troke, subsequent revascularization, or heart failure, but
his advantage is driven almost exclusively by a highly
ignificant reduction in the requirement for subsequent
evascularization. At least part of the explanation for the
ower rate of subsequent revascularization in the rescue
ngioplasty arm is simply that revascularization occurs at an
arlier point in the patient’s hospital course.
We have not demonstrated a mortality benefit by 30 days
ith rescue angioplasty compared with medical treatment.
he mortality in the rescue angioplasty arm was higher than
nticipated, particularly in patients who achieved normal
nterograde flow after rescue angioplasty. In our previous
xperience, patients with TIMI flow grade 3 upon leaving
he catheterization laboratory, irrespective of whether an-
ioplasty had been performed, had a 30-day mortality rate
f 6.9% (22). In MERLIN, the equivalent figure was 9.2%.
he higher than anticipated mortality in MERLIN may
artly be related to failure to achieve reperfusion at the
icrovascular level, despite restoration of normal antero-
rade flow in the epicardial vessel. Although 85% of patients
eft the catheterization laboratory with normal flow in the
nfarct-related vessel, only 61% had 50% ST-segment
esolution within 6 h of the initiation of fibrinolytic therapy.
he use of adjuncts such as distal protection devices during
escue angioplasty might result in more patients achieving
ptimal myocardial perfusion. It is noteworthy that the
nitiation of fibrinolytic therapy. PCI  percutaneous coronary interven-fter i
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July 21, 2004:287–96 The MERLIN Trialortality of those with persistent ST-segment elevation
fter rescue PCI (20.3%) was higher than the mortality of
hose with persistent ST-segment elevation in the conser-
ative arm (15.8%), suggesting the possibility that a failed
escue angioplasty may actually be harmful to patients.
The bleeding rate in the rescue angioplasty arm was high,
ith a requirement for transfusion in 11%. In our view, all
he transfusions administered were clinically indicated, with
o bias toward either group. The incidence of gastrointes-
inal bleeding was similar in the two groups, but unsurpris-
ngly, the rate of access complications was higher in the
escue group. The 11% rate is comparable to the major
leeding rate of 9.8% observed by Scheller et al. (23) in
atients undergoing PCI at a mean time of 3.5 h after
eceiving fibrinolytic treatment with the fibrin-specific
gent reteplase for STEMI, the transfusion rate of 9%
bserved in the Strategies for Patency Enhancement in the
mergency Department (SPEED, or Global Use of Strat-
gies To Open Occluded coronary arteries [GUSTO-4
ilot]) trial for patients with STEMI undergoing PCI at a
ean time of 63 min after reperfusion therapy began (24),
nd the transfusion rate of 8.5% observed in the Plasmin-
gen activator Angioplasty Compatibility Trial (PACT)
t-PA arm (25). We do not believe that transfusion itself
esults in an adverse outcome, and rates of this magnitude
ave recently been described as “low” (26). However, in
ontrast to these three trials, in which the use of PCI soon
fter reperfusion therapy did not result in transfusion rates
ignificantly different from those seen in the comparator
rms, the transfusion rate in the rescue arm of MERLIN
as significantly higher than that in the conservative arm.
ne explanation for this is the long half-life of streptoki-
ase, compared with the fibrin-specific lytic agents. How-
ver, the transfusion rate was much lower than that observed
n historical trials of PCI after streptokinase (27).
The explanation for the number of strokes in the rescue
rm is uncertain. To our knowledge, this has not been
reviously observed. However, the 95% CI around the
bsolute RD is large (and includes a 0.5% absolute RD). It
s therefore possible that the observed difference is partly
ue to chance. In addition, one stroke in the rescue arm
ccurred in a patient who did not undergo coronary angiog-
aphy or rescue PCI but is included in the analysis on an
ntention-to-treat basis. We have speculated that the com-
ination of antiplatelet agents administered so soon after
brinolysis may be responsible for thromboembolic events
rom LV thrombus (1 stroke occurred in a patient with
ocumented LV thrombus), but we have no proof for this
heory. We cannot exclude cerebral hemorrhage as a cause
or events in those patients who did not undergo computed
omographic scanning, but there is no evidence to suggest
hat these events were due to this mechanism.
The benefits of rescue angioplasty observed in this trial
re small, the principle effect being a reduced requirement
or subsequent revascularization. Although some of these
ubsequent revascularizations are “expected” (for example,fter a positive exercise test), the vast majority of subsequent
evascularizations were performed for re-infarction or on-
oing unstable ischemia. This benefit of rescue angioplasty
s achieved at the expense of more strokes and more
ransfusions and with no early preservation of LV systolic
unction. Pending results of other ongoing trials of rescue
ngioplasty, with particular reference to the pharmacologic
reatment and technical aspects of the rescue angioplasty
rocedure, it is currently reasonable to pursue a policy of
atchful waiting in patients with failed fibrinolysis. How-
ver, our results are perhaps less applicable to those receiv-
ng initial therapy with fibrin-specific lytic agents and do
ot preclude the selective use of rescue angioplasty for those
ith ongoing chest pain or extensive ST-segment changes,
or are they relevant in the context of immediate or
acilitated angioplasty. Rescue angioplasty might also be
ore appropriate offered later after fibrinolysis, but this
equires further study.
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